Kathryn M. Monroe

Kathryn M. Monroe

Auto-generated profile, based on publicly available information

Kathryn M. Monroe

Denali Therapeutics Inc., South San Francisco, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Neuron
Verified
Journal Article
Closed access
ANAlicia A. Nugent
Alicia A. Nugent
KLKarin Lin
Karin Lin
BLBettina van Lengerich
Bettina van Lengerich
SLSteve Lianoglou
Steve Lianoglou
LPLaralynne Przybyla
Laralynne Przybyla
GPGilbert Di Paolo
Gilbert Di Paolo

12 January 2023 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
BLBettina van Lengerich
Bettina van Lengerich
LZLihong Zhan
Lihong Zhan
DXDan Xia
Dan Xia
DCDarren Chan
Darren Chan
DJDavid Joy
David Joy
KMKathryn M. Monroe
Kathryn M. Monroe
Loss-of-function variants of TREM2 are associated with increased risk of Alzheimer’s disease (AD), suggesting that activation of this innate immune receptor may be a useful therapeutic strategy. Here we describe a high-affinity human TREM2-activating antibody engineered with a monovalent transferrin receptor (TfR) binding site, termed antibody transport vehicle (ATV), to facilitate blood–brain barrier transcytosis. Upon peripheral delivery in mice, ATV:TREM2 showed improved brain biodistribution and enhanced signaling compared to a standard anti-TREM2 antibody. In human induced pluripotent stem cell (iPSC)-derived microglia, ATV:TREM2 induced proliferation and improved mitochondrial metabolism. Single-cell RNA sequencing and morphometry revealed that ATV:TREM2 shifted microglia to metabolically responsive states, which were distinct from those induced by amyloid pathology. In an AD mouse model, ATV:TREM2 boosted brain microglial activity and glucose metabolism. Thus, ATV:TREM2 represents a promising approach to improve microglial function and treat brain hypometabolism found in patients with AD.

12 January 2022 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
ARAnika Reifschneider
Anika Reifschneider
SRSophie Robinson
Sophie Robinson
BLBettina van Lengerich
Bettina van Lengerich
JGJohannes Gnörich
Johannes Gnörich
TLTodd Logan
Todd Logan
CHChristian Haass
Christian Haass
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

24 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
AFAstrid F. Feiten
Astrid F. Feiten
KDKilian Dahm
Kilian Dahm
KSKai Schlepckow
Kai Schlepckow
BLBettina van Lengerich
Bettina van Lengerich
JSJung H. Suh
Jung H. Suh
CHChristian Haass
Christian Haass
Triggering receptor expressed on myeloid cells 2 (TREM2) is a central regulator of microglial activity and loss-of-function coding variants are major risk factors for late onset Alzheimer’s disease (LOAD). To better understand the molecular and functional changes associated with TREM2 signalling in microglia, we generated a TREM2 reporter mouse. In APP transgenic animals, bulk RNA-sequencing of isolated microglia sorted based on reporter expression highlighted TREM2 level-related changes in major immunometabolic pathways, and enrichment of genes in oxidative phosphorylation and cholesterol metabolism in microglia with increased TREM2 expression. Metabolic and lipidomic profiling of sorted microglia showed that, independent of Aβ pathology, TREM2 expression correlated with signatures consistent with increased cellular redox, energetics, and cholesterol homoeostasis. In accordance, metabolic activity correlated with phagocytic capacity. Finally, we performed chronic treatment with a TREM2 agonist antibody and identified a window of TREM2 expression where microglia are most responsive, thereby informing clinical applications of TREM2 agonists.

16 February 2026 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
KMKathryn M. Monroe
Kathryn M. Monroe
SHSoyon Hong
Soyon Hong
JLJoseph W. Lewcock
Joseph W. Lewcock
AYAndrew C. Yang
Andrew C. Yang

3 December 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
TWTanya N. Weerakkody
Tanya N. Weerakkody
HSHanna Sabelström
Hanna Sabelström
SAShan V. Andrews
Shan V. Andrews
JCJean Paul Chadarevian
Jean Paul Chadarevian
MCMarcus Y. Chin
Marcus Y. Chin
KMKathryn M. Monroe
Kathryn M. Monroe
The Alzheimer’s disease (AD) genetic landscape identified microglia as a key disease-modifying cell type. Paired immunoglobulin-like type 2 receptor alpha (PILRA) is an immunoreceptor tyrosine–based inhibitory motif domain–containing inhibitory receptor, expressed by myeloid cells such as microglia. The known protective PILRA G78R gene variant reduces AD risk in apolipoprotein E4 ( APOE4 ) carriers and is enriched in a cohort of healthy centenarians. However, mechanisms underlying protective effects in microglia are undefined. Here, we identified biological functions of PILRA in human induced pluripotent stem cell–derived microglia (iMG) and chimeric AD mice. PILRA knockout (KO) in iMG rescued ApoE4-mediated immunometabolic deficits and prevented lipotoxicity through increased lipid storage, improved mitochondrial bioenergetics, and antioxidant activity. PILRA KO also enhanced microglial chemotaxis and attenuated inflammation. With pharmacological inhibitor studies, we showed that peroxisome proliferator–activated receptor and signal transducer and activator of transcription 1/3 mediated PILRA -dependent microglial functions. AD mice transplanted with human PILRA KO microglia exhibited reduced amyloid pathology and rescued synaptic markers. A high-affinity ligand blocking PILRA antibody phenocopied PILRA KO iMG. These findings suggest that PILRA is a pharmacologically tractable therapeutic target for AD.